References
- 1. Trifan, A., Gheorge, C., Dumitraşcu, D., Diculescu, M., Gheorghe, L., Sporea, I., Ciurea, T. (2018). Gastroenterologie iş Hepatologie Clinicã. Bucharest: Editura Medicalã.
- 2. Barb, D., Repetto, E. M., Stokes, M. E., Shankar, S. S., & Cusi, K. (2021). Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic liver disease. Obesity: The Journal of the Obesity Society, 11. doi:10.1002/oby.2326310.1002/oby.2326334553836
- 3. Clark, J. M., & Diehl, A. M. (2003). Nonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogenic Cirrhosis. The Journal of the American Medical Association. doi:10.1001/jama.289.22.300010.1001/jama.289.22.300012799409
- 4. Onzi, G., Moretti, F., Balbinot, S. S., Balbinot, R. A., & Soldera, J. (2019). Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis. (G.-W. Cao, Ed.) Hepatoma Research. doi:10.20517/2394-5079.2018.11410.20517/2394-5079.2018.114
- 5. Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Bonino, F. (2016). Pathophysiology of Non Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences. doi:10.3390/ijms1712208210.3390/ijms17122082518788227973438
- 6. Severson, T. J., Besur, S., & Bonkovsky, H. L. (2016). Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World Journal of Gastroenterology(22(29)), 6742-6756. doi:10.3748/wjg.v22.i29.674210.3748/wjg.v22.i29.6742497047927547017
- 7. Poianã, C., & Fica, S. (2015). Endocrinologie pentru studenţi şi rezidenţi. Bucharest: Editura Universitara „Carol Davila” Bucure?ti.
- 8. Lujan, P. V., Esmel, E. V., & Meseguer, E. S. (2021). Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. MDPI(13(5)). doi:https://doi.org/10.3390/nu1305144210.3390/nu13051442814587733923255
- 9. Rada, P., Gonzalez-Rodrigues, A., Carmelo, G.-M., & Valverde, A. M. (2020). Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver. Cell Death and Disease. doi:https://doi.org/10.1038/s41419-020-03003-w10.1038/s41419-020-03003-w751968532978374
- 10. Chen, Z., Tian, R., She, Z., Cai, J. & Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic. Biol. Med. 152, 116-141 (2020)
- 11. Ibrahim, S. H., Kohli, R. & Gores, G. J. Mechanisms of lipotoxicity in NAFLD and clinical implications. J. Pediatr. Gastroenterol. Nutr. 53, 131-140 (2011)
- 12. Hirsova, P. et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 150, 956-967 (2016)10.1053/j.gastro.2015.12.037480846426764184
- 13. Koyama, Y. & Brenner, D. A. Liver inflammation and fibrosis. J. Clin. Invest 127, 55-64 (2017).10.1172/JCI88881519969828045404
- 14. Arrese, M., Cabrera, D., Kalergis, A. M. & Feldstein, A. E. Innate immunity and inflammation in NAFLD/NASH. Dig. Dis. Sci. 61, 1294-1303 (2016)
- 15. Pardo, V., Gonzalez-Rodriguez, A., Guijas, C., Balsinde, J. & Valverde, A. M. Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activation. J. Biol. Chem. 290, 11663-11677 (2015)
- 16. Kazankov, K. et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature reviews. GNat. Rev. Gastroenterol. Hepatol. 16, 145-159 (2019).
- 17. Chu, X. et al. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading. J. Transl. Med. 16, 108 (2018)10.1186/s12967-018-1490-y593782029690903
- 18. Li, B. H., He, F. P., Yang, X., Chen, Y. W. & Fan, J. G. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl. Res. 180, 103-117 (2017).
- 19. Tsuchida, T., and Friedman, S. L. (2017). Mechanisms of Hepatic Stellate Cell Activation. Nat. Rev. Gastroenterol. Hepatol. 14 (7), 397-411. doi:10.1038/nrgastro.2017.3810.1038/nrgastro.2017.3828487545
- 20. G. Targher, M. Chonchol, G. Zoppini, C. Abaterusso, and E. Bonora, “Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?” Journal of Hepatology, vol. 54, no. 5, pp. 1020-1029, 2011.
- 21. J. H. Ix and K. Sharma, “Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK,” Journal of the American Society of Nephrology, vol. 21, no. 3, pp. 406-412, 2010.10.1681/ASN.2009080820447325420150538
- 22. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, et al. The incidence and risk factors of hepatocellular carcinoma in Onzi et al. Hepatoma Res 2019;5:7 I http://dx.doi.org/10.20517/2394-5079.2018.114 Page 5 of 7 patients with non-alcoholic steatohepatitis. Hepatology 2010;51:1972-8
- 23. Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management. World J Hepatol 2017;9:533-4310.4254/wjh.v9.i11.533539580228469809
- 24. Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-70310.1111/apt.14937749549430136293
- 25. Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. (2019). Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Liver Disease. Gastroenterology. doi: 10.1053/j.gastro.2018.12.03610.1053/j.gastro.2018.12.036750505230660725
- 26. Valeria Annarita Piazzolla, Alessandra Mangia. (2020). Noninvasive Diagnosis of NAFLD and NASH. Cells. doi: 10.3390/cells904100510.3390/cells9041005722647632316690
- 27. G. Thomas Brown, David E. Kleiner. (2016). Histopathology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Metabolism. doi: 10.1016/j.metabol.2015.11.00810.1016/j.metabol.2015.11.008488954726775559
- 28. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(42): 15539-15548 [PMID: 25400438 DOI: 10.3748/wjg.v20.i42.15539]10.3748/wjg.v20.i42.15539422951925400438
- 29. Arjun J. Sanyal, Elizabeth M. Brunt, David E. Kleiner, Kris Kowdley, Naga Chalasani, Joel Lavine, Vlad Ratziu, Arthur McCullough. (2011). Endpoints and Clinical Trial Design for Nonalcoholic Steatohepatitis. Hepatology. 2011 Jul; 54(1): 344-353. doi: 10.1002/hep.2437610.1002/hep.24376401446021520200
- 30. Sweta Tandra, Matthew M. Yeh, Elizabeth M. Brunt, Raj Vuppalanchi, Oscar W. Cummings, Aynur Ünalp-Arida, Laura A. Wilson, Naga Chalasani. Presence and Significance of Microvesicular Steatosis is Nonalcoholic Fatty Liver Disease. Journal of Hepatology. 2011 Sep; 55(3): 654-659. doi: 10.1016/j.jhep.2010.11.02110.1016/j.jhep.2010.11.021313978021172393
- 31. G. Celebi, A.F. Cicek, H. Gurel, H. Genc, A.Kirik, C.N. Ercin, T. Dogru. Microvesicular steatosis : a missed item in the management of nonalcoholic fatty liver disease? Acta Gastro-Enterologica Belgica. Oct-Dec 2020;83(4): 565-570. PMID: 33321012
- 32. Naga Chalasani, Laura Wilson, David E. Kleiner, Oscar W Cummings, Elizabeth M. Brunt, Aynur Ünalp. (2008). Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2008 May; 48(5): 829-834. doi: 10.1016/j.jhep.2008.01.01610.1016/j.jhep.2008.01.016
- 33. Hongfa Zhu, Henry C. Bodenheimer Jr, David J. Chain, Albert D. Min, Neil D. Theise. (2010). Hepatic lipogranulomas in patients with chronic liver disease: Association with hepatitis C and fatty liver disease. World Journal of Gastroenterology. 2010 Oct 28; 16(40): 5065-5069. doi: 10.3748/wjg.v16.i40.506510.3748/wjg.v16.i40.5065
- 34. Elizabeth M. Brunt, David E. Kleiner, Laura A. Wilson, Aynur Ünalp, Cynthia E. Behling, Joel E. Lavine, Brent A. Neushwander-Tetri and the NASH Clinical Research Network. (2009). Portal Chronic Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology. 2009 Mar; 49(3): 809-820. doi: 10.1002/hep.2272410.1002/hep.22724
- 35. Petra Hirsova, Gregory J. Gores. Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology. 2015 Jan; 1(1): 17-27. doi: 10.1016/j.jcmgh.2014.11.00510.1016/j.jcmgh.2014.11.005
- 36. Veronika Zámbó, Laura Simon-Szabó, Péter Szelényi, Éva Kereszturi, Gábor Bánhegyi, Miklós Csala. Lipotoxicity in the liver. World Journal of Hepatology. 2013 Oct 27; 5(10): 550-557. doi: 10.4254/wjh. v5.i10.550
- 37. Stephen H. Caldwell, Vanessa D. Lee, David E. Kleiner, Abdullah M.S. Al-Osaimi, Curtis K. Argo, Patrick G. Northup, Carl L. Berg. Nash and cryptogenic cirrhosis: A histological analysis. Annals of Hepatology. 2009 Oct-Dec; 8(4): 346-352. PMCID: PMC838124310.1016/S1665-2681(19)31748-X
- 38. Metin Basaranoglu, Nesrin Turhan, Abdullah Sonsuz, Gökcen Basaranoglu. Mallory-Denk bodies in chronic hepatitis. World Journal of Gastroenterology. 2011 May 7; 17(17): 2172-2177. doi: 10.3748/wjg.v17.i17.217210.3748/wjg.v17.i17.2172309286721633525
- 39. Mariana Verdelho Machado, Duarte M. S. Ferreira, Rui E. Castro, Ana Rita Silvestre, Teresinha Evanghelista, João Coutinho, Fátima Carepa, Adília Costa, Cecília M. P. Rodrigues, Helena Cortez-Pinto. Liver and Muscle in Morbid Obesity: The interplay of Fatty Liver and Insulin Resistance. PLoS One. 2012;7(2):e31738. doi: 10.1371/journal.pone.003173810.1371/journal.pone.0031738328100522359625
- 40. Gherasim, L. (1999). Medicinã Internã: Vol. III - Bolile digestive, hepatice şi pancreatice. Bucharest: Editura Medicalã
- 41. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402.10.1016/j.jhep.2015.11.00427062661
- 42. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risc factors and diagnosis. Expert Rev Gastroenterol Hepatol 2010; 4: 623-35.10.1586/egh.10.5620932147
- 43. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.10.1186/1471-230X-6-33163665117081293
- 44. Gastaldelli A, Kozakova M, Højlund K, et al. RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-4410.1002/hep.2284519291789
- 45. Balkau B, Lange C, Vol S, Fumeron F. Group Study D.E.S.I.R Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56.10.1186/1471-230X-10-56289884520529259
- 46. Kozakova M, Palombo C, Paterni M, et al. The RISC Investigators. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. Hepatology 2012; 55: 1406-15.10.1002/hep.2555522334565
- 47. Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-60.10.1111/j.1365-2036.2011.04668.x21517924
- 48. Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-12.10.1148/radiol.239105036116484355
- 49. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut. 2007;56:1760-1769.10.1136/gut.2006.112094209570717911352
- 50. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48:993-999.10.1016/j.jhep.2008.02.011242346718395287
- 51. Simopoulos AP. Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. Nutrients. 2013;5:2901-2923.10.3390/nu5082901377523423896654
- 52. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology 2010; 51:121.10.1002/hep.23276279953819827166
- 53. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty livers disease: a systematic review and meta-analysis. J Hepatol 2012; 57:157.10.1016/j.jhep.2012.02.02322414768
- 54. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149:367.10.1053/j.gastro.2015.04.005
- 55. S.E. Keating, J. George, N.A. Johnson. The benefits of exercise for patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol., 9 (2015), pp. 1247-1250.
- 56. S. Zelber-Sagi, A. Buch, H. Yeshua, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial World J Gastroenterol., 20 (2014), pp. 4382-4392.
- 57. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.10.1056/NEJMra041001
- 58. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-525.10.1111/j.1572-0241.2001.03553.x
- 59. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176-1184.10.1053/j.gastro.2008.06.047
- 60. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-110.10.1053/j.gastro.2008.03.078
- 61. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;29:172-182.10.1111/j.1365-2036.2008.03869.x
- 62. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464-1467.10.1002/hep.510230624
- 63. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999;31:384.10.1016/S0168-8278(99)80243-8
- 64. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485-2490.10.1111/j.1572-0241.2003.08699.x14638353
- 65. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-419.10.1053/jhep.2003.5031612883485
- 66. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int. 2006;26:1015-1017.10.1111/j.1478-3231.2006.01315.x16953843
- 67. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43:173-181.10.1002/hep.21006292542416374859
- 68. Stephen A Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad H Younes, Bradley Freilich, Muhammad Y Sheikh, Jörn M Schattenberg, Zeid Kayali, Adam Zivony, Aasim Sheikh, Javier Garcia-Samaniego, Sanjaya K Satapathy, George Therapondos, Edward Mena, Detlef Schuppan, James Robinson, Jean L Chan, David T Hagerty, Arun J Sanyal. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. Journal of Hepatology. 2020. DOI: 10.1016/j.jhep.2019.11.02410.1016/j.jhep.2019.11.02431887369